Publication:

The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension

Loading...
Thumbnail Image

Date

2017

Journal Title

Journal ISSN

Volume Title

Publisher

Springer Berlin Heidelberg
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Gibbons, C. H., P. Schmidt, I. Biaggioni, C. Frazier-Mills, R. Freeman, S. Isaacson, B. Karabin, et al. 2017. “The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension.” Journal of Neurology 264 (8): 1567-1582. doi:10.1007/s00415-016-8375-x. http://dx.doi.org/10.1007/s00415-016-8375-x.

Abstract

Neurogenic orthostatic hypotension (nOH) is common in patients with neurodegenerative disorders such as Parkinson’s disease, multiple system atrophy, pure autonomic failure, dementia with Lewy bodies, and peripheral neuropathies including amyloid or diabetic neuropathy. Due to the frequency of nOH in the aging population, clinicians need to be well informed about its diagnosis and management. To date, studies of nOH have used different outcome measures and various methods of diagnosis, thereby preventing the generation of evidence-based guidelines to direct clinicians towards ‘best practices’ when treating patients with nOH and associated supine hypertension. To address these issues, the American Autonomic Society and the National Parkinson Foundation initiated a project to develop a statement of recommendations beginning with a consensus panel meeting in Boston on November 7, 2015, with continued communications and contributions to the recommendations through October of 2016. This paper summarizes the panel members’ discussions held during the initial meeting along with continued deliberations among the panel members and provides essential recommendations based upon best available evidence as well as expert opinion for the (1) screening, (2) diagnosis, (3) treatment of nOH, and (4) diagnosis and treatment of associated supine hypertension. Electronic supplementary material The online version of this article (doi:10.1007/s00415-016-8375-x) contains supplementary material, which is available to authorized users.

Description

Research Data

Keywords

Neurogenic orthostatic hypotension, Supine hypertension, Autonomic dysfunction, Droxidopa, Midodrine, Fludrocortisone

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories